First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer
Randy Yeh,Joseph A O'Donoghue,Vetri Sudar Jayaprakasam,Audrey Mauguen,Ryan Min,Sue Park,Julia P Brockway,Jacqueline F Bromberg,W Iris Zhi,Mark E Robson,Rachel Sanford,Shanu Modi,Brian J Agnew,Serge K Lyashchenko,Jason S Lewis,Gary A Ulaner,Brian M Zeglis,Joseph A. O’Donoghue,Julia P. Brockway,Jacqueline F. Bromberg,Mark E. Robson,Brian J. Agnew,Serge K. Lyashchenko,Jason S. Lewis,Gary A. Ulaner,Brian M. Zeglis
DOI: https://doi.org/10.2967/jnumed.123.266392
2024-03-02
Journal of Nuclear Medicine
Abstract:Radioimmunoconjugates targeting human epidermal growth factor receptor 2 (HER2) have shown potential to noninvasively visualize HER2-positive tumors. However, the stochastic approach that has been traditionally used to radiolabel these antibodies yields poorly defined and heterogeneous products with suboptimal in vivo performance. Here, we describe a first-in-human PET study on patients with HER2-positive breast cancer evaluating the safety, biodistribution, and dosimetry of 89 Zr-site-specific (ss)-pertuzumab PET, a site-specifically labeled radioimmunoconjugate designed to circumvent the limitations of random stochastic lysine labeling. Methods: Six patients with HER2-positive metastatic breast cancer were enrolled in a prospective clinical trial. Pertuzumab was site-specifically modified with desferrioxamine (DFO) via a novel chemoenzymatic strategy and subsequently labeled with 89 Zr. Patients were administered 74 MBq of 89 Zr-ss-pertuzumab in 20 mg of total antibody intravenously and underwent PET/CT at 1 d, 3–4 d, and 5–8 d after injection. PET imaging, whole-body probe counts, and blood draws were performed to assess the pharmacokinetics, biodistribution, and dosimetry. Results: 89 Zr-ss-pertuzumab PET/CT was used to assess HER2 status and heterogeneity to guide biopsy and decide the next line of treatment at progression. The radioimmunoconjugate was able to detect known sites of malignancy, suggesting that these tumor lesions were HER2-positive. The optimal imaging time point was 5–8 d after administration, and no toxicities were observed. Dosimetry estimates from OLINDA showed that the organs receiving the highest doses (mean ± SD) were kidney (1.8 ± 0.5 mGy/MBq), liver (1.7 ± 0.3 mGy/MBq), and heart wall (1.2 ± 0.1 mGy/MBq). The average effective dose for 89 Zr-ss-pertuzumab was 0.54 ± 0.03 mSv/MBq, which was comparable to both stochastically lysine-labeled 89 Zr-DFO-pertuzumab and 89 Zr-DFO-trastuzumab. One patient underwent PET/CT with both 89 Zr-ss-pertuzumab and 89 Zr-DFO-pertuzumab 1 mo apart, with 89 Zr-ss-pertuzumab demonstrating improved lesion detection and higher tracer avidity. Conclusion: This study demonstrated the safety, dosimetry, and potential clinical applications of 89 Zr-ss-pertuzumab PET/CT. 89 Zr-ss-pertuzumab may detect more lesions than 89 Zr-DFO-pertuzumab. Potential clinical applications include real-time evaluation of HER2 status to guide biopsy and assist in treatment decisions.
radiology, nuclear medicine & medical imaging